Patients in the no LND arm had shorter surgery duration, less blood loss, and reduced postoperative hospital stay compared to ...

Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic ...

Active surveillance (AS) appears to be a durable and safe long-term management strategy for patients with small, low-risk papillary thyroid cancer (PTC), with durability and age strongly correlated, ...

In recognition of October as Breast Cancer Awareness Month, Sarah Premji, MD, assistant director of Breast Cancer Research at Sarah Cannon Research Institute (SCRI), discusses exciting advancements in ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

NBTXR3 combined with radiotherapy and ICIs showed a 47.4% objective response rate and 78.9% disease control rate in melanoma ...

Harpreet Singh, MD, former Director of the Division of Oncology 2 at the FDA, noted the importance of considering the global regulatory environment in the development of radiopharmaceuticals. This is ...

Cintredekin besudotox targets IL-12 alpha-2 receptor-expressing tumor cells, using convection-enhanced delivery to bypass the ...

Casdatifan activates hundreds of genes in response to low oxygen levels, and when oxygen levels return to normal, HIF-2a is ...

Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...

Patients who progressed on first- or second-line therapy were the population evaluated in the CABINET trial (NCT03375320). Anthony suggests that patients with pancreatic and pulmonary NETs, ...